SAN DIEGO, CA--(Marketwired - August 05, 2014) -
Aegis announced today that it is offering an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray diabetes drug. Exenatide is a 39-amino acid synthetic peptide GLP-1 analog highly effective in controlling blood glucose levels in Type-2 diabetes. All currently available GLP-1 analogs require injection. The currently marketed injectable form of exenatide, sold under the trademark Byetta®, requires twice daily injections. The Aegis patented Intravail® based formulation of exenatide provides equivalent blood levels using a simple metered nasal spray to replace each of the two daily injections. The total market for GLP-1 analogs is expected to grow to $5 billion within the next few years. As the only non-injectable option for patients seeking to avoid needles, needlestick injuries, and syringe disposal problems, the non-injectable Aegis nasal spray exenatide formulation is poised to achieve significant market share.
For licensing inquiries, please contact Ralph Barry.
About Aegis Therapeutics
Aegis Therapeutics LLC commercializes its patented drug formulation technologies through product-specific licenses. Intravail® drug delivery technology enables non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding oxidative damage caused by polysorbate surfactants.
For more information about Aegis, please visit: http://www.aegisthera.com.